These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 8996848)

  • 41. The 2nd Calibration and Validation Group workshop on recent issues in good laboratory practice bioanalysis.
    Savoie N; Booth BP; Bradley T; Garofolo F; Hughes NC; Hussain S; King SP; Lindsay M; Lowes S; Ormsby E; Phull R; Rocci ML; Vallano PT; Viau A; Zhu Z
    Bioanalysis; 2009 Apr; 1(1):19-30. PubMed ID: 21083184
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Examining outlying subjects and outlying records in bioequivalence trials.
    Wang W; Chow SC
    J Biopharm Stat; 2003 Feb; 13(1):43-56. PubMed ID: 12635902
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The subject-by-formulation interaction in multivariate bioequivalence.
    Cao L; Mathew T
    J Biopharm Stat; 2007; 17(3):367-79. PubMed ID: 17479387
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bioavailability of psychotropic drugs: historical perspective and pharmacokinetic overview.
    Ereshefsky L; Jann MW; Saklad SR; Davis CM
    J Clin Psychiatry; 1986 Sep; 47 Suppl():6-15. PubMed ID: 3528134
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impact of outlying subjects on decision of bioequivalence.
    Ki FY; Liu JP; Wang W; Chow SC
    J Biopharm Stat; 1995 Mar; 5(1):71-94. PubMed ID: 7613561
    [TBL] [Abstract][Full Text] [Related]  

  • 46. On a reasonable disaggregate criterion of population bioequivalence admitting of resampling-free testing procedures.
    Wellek S
    Stat Med; 2000 Oct; 19(20):2755-67. PubMed ID: 11033573
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of changing the bioequivalence range from (0.80, 1.20) to (0.80, 1.25) on the power and sample size.
    Steinijans VW; Hauck WW; Diletti E; Hauschke D; Anderson S
    Int J Clin Pharmacol Ther Toxicol; 1992 Dec; 30(12):571-5. PubMed ID: 1473872
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Towards a practical strategy for assessing individual bioequivalence. Food and Drug Administration Individual Bioequivalence Working Group.
    Schall R; Williams RL
    J Pharmacokinet Biopharm; 1996 Feb; 24(1):133-49. PubMed ID: 8827586
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Extension to the use of tolerance intervals for the assessment of individual bioequivalence.
    Esinhart JD; Chinchilli VM
    J Biopharm Stat; 1994 Mar; 4(1):39-52. PubMed ID: 8019583
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PhRMA perspective on population and individual bioequivalence.
    Barrett JS; Batra V; Chow A; Cook J; Gould AL; Heller AH; Lo MW; Patterson SD; Smith BP; Stritar JA; Vega JM; Zariffa N
    J Clin Pharmacol; 2000 Jun; 40(6):561-70. PubMed ID: 10868305
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acceptable and unacceptable procedures in bioavailability and bioequivalence trials.
    Marzo A; Ceppi Monti N
    Pharmacol Res; 1998 Nov; 38(5):401-4. PubMed ID: 9806821
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The transitivity of bioequivalence testing: potential for drift.
    Anderson S; Hauck WW
    Int J Clin Pharmacol Ther; 1996 Sep; 34(9):369-74. PubMed ID: 8880284
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Estimating product bioequivalence for highly variable veterinary drugs.
    Claxton R; Cook J; Endrenyi L; Lucas A; Martinez MN; Sutton SC
    J Vet Pharmacol Ther; 2012 Apr; 35 Suppl 1():11-6. PubMed ID: 22413787
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Estimating treatment means in a mixed-effect ANOVA model for bioequivalence studies.
    Hsuan FC
    Biometrics; 1993 Sep; 49(3):703-13. PubMed ID: 8241367
    [TBL] [Abstract][Full Text] [Related]  

  • 55. On statistical power for average bioequivalence testing under replicated crossover designs.
    Wan H; Chow SC
    J Biopharm Stat; 2002 Aug; 12(3):295-309. PubMed ID: 12448572
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of some properties of individual bioequivalence (IBE) from replicate-design studies.
    Tothfalusi L; Endrenyi L
    Int J Clin Pharmacol Ther; 2001 Apr; 39(4):162-6. PubMed ID: 11332872
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Consumer's risk in the EMA and FDA regulatory approaches for bioequivalence in highly variable drugs.
    Muñoz J; Alcaide D; Ocaña J
    Stat Med; 2016 May; 35(12):1933-43. PubMed ID: 26707698
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comment on so-called individual criteria of bioequivalence.
    Wellek S
    J Biopharm Stat; 1997 Mar; 7(1):17-21. PubMed ID: 9056583
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Bioequivalence of solid drug preparation].
    Ejima A
    Eisei Shikenjo Hokoku; 1982; (100):1-20. PubMed ID: 6897833
    [No Abstract]   [Full Text] [Related]  

  • 60. Some statistical considerations on the FDA draft guidance for individual bioequivalence.
    Hsuan FC
    Stat Med; 2000 Oct; 19(20):2879-84. PubMed ID: 11033582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.